Comparative Pharmacology
Head-to-head clinical analysis: SPRYCEL versus TEPMETKO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SPRYCEL versus TEPMETKO.
SPRYCEL vs TEPMETKO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dasatinib is a dual tyrosine kinase inhibitor targeting BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. It binds to the ATP-binding site of BCR-ABL and inhibits proliferation and induces apoptosis in Philadelphia chromosome-positive (Ph+) leukemic cells.
Tepotinib is a highly selective, ATP-competitive inhibitor of the mesenchymal-epithelial transition (MET) receptor tyrosine kinase, including the MET exon 14 skipping variant. It inhibits MET phosphorylation and downstream signaling pathways, thereby reducing tumor cell proliferation and migration.
100 mg orally once daily, with or without food.
450 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 3–4 hours for dasatinib, with a longer half-life of 8–10 hours for its active metabolite; clinical context: supports twice-daily dosing.
Terminal elimination half-life approximately 12-15 hours in patients, supporting twice-daily dosing.
Primarily fecal (85%) as unchanged drug and metabolites; renal excretion accounts for <10% of the dose.
Primarily fecal (≥80% of absorbed dose), with renal excretion accounting for <5% as unchanged drug.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor